Vicuron Pharmaceuticals Inc.

Naicons S.c.a.r.l.

Sentinella Pharmaceuticals, Inc.

Gianpaolo Candiani

Enrico Selva

Flavia Marinelli

Daniele Losi

Luciano Gastaldo

Ameriga Lazzarini

Ismaela Ciciliato

Franco Parenti

Romeo Ciabatti

Gianbattista Panzone

Francesco Parenti

Giacomo Carenzi

Marco Cavaleri

Sonia Maffioli

Anna Checchia

Gabriella Romano

Paola Turconi

Lucia Carrano

The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation ofsp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such asspecies andand Mycobacteria.

Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof

The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation ofsp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891, which is a complex comprising two Factors, denominated Factors A1 and A2, has a peptide structure containing lanthionine and methyllanthionine as constituents which are typical characteristics of the antibiotics of the lantibiotics group. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such asspecies andand

The invention relates to an antibiotic substance of microbial origin, arbitrarily denominated antibiotic 107891 which is produced by fermentation ofsp. ATCC PTA-5024, the pharmaceutically acceptable salts and compositions thereof, and their use as an antibacterial agent having inhibitory activity versus susceptible microbes. Antibiotic 107891 and its Factors A1 and A2 show a good antibacterial activity against Gram-positive bacteria including methicillin resistant and vancomycin resistant strains, and is active also against some Gram-negative bacteria such asspecies andand

The invention regards a process for the production of ramoplanin-like derivatives of formula (I): RAMO-NC&#x2014;CO&#x2014;R (I), wherein the radical R represents a hydrocarbon radical and the portion RAMO-NH&#x2014; represents deacylated ramoplanin, any of its factors or ramoplanose. The compound of Formula (I) are obtained by reacting a carboxylic acid R&#x2014;COOH with deacylated ramoplanin, any of its factors or ramoplanose protected on the ornitine amino groups. New compounds wherein the hydrocarbon radical R is different form those characaterizing the ramoplanin and ramoplanose natural products and their tetrahydro-derivatives are calimed. The new compounds have the same or better antinfective activity, lower haemolytic effect and better tolerability profile than ramoplanin.

Process for the production of ramoplanin-like amide derivatives

The present invention relates to a pharmaceutical composition for intravenous administration that contains ramoplanin or a member of the ramoplanin family.

Injectable formulations containing ramoplanin

Growing community of inventors

Gorgonzola, Italy

Gianpaolo Candiani